LifeMD FY2025 rev $194.1M (+25%), adj EBITDA $15.3M (+309%); guides to >$250M run-rate by Q4 2026

LifeMD, Inc.

FY2025 revenue $194.1M (+25% YoY); adjusted EBITDA $15.3M (+309% YoY).
Q4 2025 revenue $46.9M (+4% YoY); adjusted EBITDA $4.8M (+348% YoY).
Launched oral Wegovy post-year-end; >80% of new weight management patients using branded therapy; Q1 sign-ups at record levels.
Ended 2025 with $36.8M cash, no debt; guides to annualized revenue >$250M and adj EBITDA >$25M by Q4 2026.
Benefits infrastructure on track to cover ~220M Americans in Q2 2026; women's health seeing strong early growth.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LifeMD, Inc. reported the year ended December 31, 2025 results: revenue $194.1 million. Guidance initiated.

Period: the year ended December 31, 2025
Revenue: $194.1 million
Guidance: initiated
Result: reported results

Exact text from the filing

Full year 2025 revenue grew 25% to $194.1 million; adjusted EBITDA rose 309% to $15.3 million.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LifeMD, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $46.9 million. Guidance initiated.

Period: the fourth quarter ended December 31, 2025
Revenue: $46.9 million
Guidance: initiated
Result: reported results

Exact text from the filing

Fourth quarter revenue increased 4% to $46.9 million; adjusted EBITDA rose 348% to $4.8 million.

View on SEC.gov

Browse all earnings releases →

LifeMD, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-009380

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.